Anne Peters, MD

Articles by Anne Peters, MD

Representativeness of Dipeptidyl-Peptidase-4 Inhibitor Cardiovascular Outcomes Trials

ByJoanna P. MacEwan, PhD,John J Sheehan, PhD,Anne Peters, MD,Jacqueline Vanderpuye-Orgle, PhD,Iftekhar Kalsekar, PhD,Anup Malani, PhD

September 20th 2016

Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

ByMichael E. Chernew, PhD,Rick McKellar, BS,Wade Aubry, MD,Roy Beck, MD, PhD,Joshua Benner, PharmD, ScD,Jan E. Berger, MD, MJ,A. Mark Fendrick, MD,Felicia Forma, BSc,Dana Goldman, PhD,Anne Peters, MD,Rebecca Killion, MA,Darius Lakdawalla, PhD,Douglas K. Owens, MD,Joe Stahl, MA

July 2nd 2013

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

February 12th 2013

Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.

Latest Updated Articles

Representativeness of Dipeptidyl-Peptidase-4 Inhibitor Cardiovascular Outcomes Trials
September 20th 2016
Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
February 12th 2013
Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
July 2nd 2013

Anne Peters, MD

Articles by Anne Peters, MD

Representativeness of Dipeptidyl-Peptidase-4 Inhibitor Cardiovascular Outcomes Trials

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

Latest Updated Articles

Trending on AJMC

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD